{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:03:47Z","timestamp":1756425827738,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,5,11]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>A 69-year-old retired miner with stage 4 non-small-cell lung cancer presented with a 2-month history of obstructive liver function tests following nivolumab immunotherapy. His case had not responded to high dose prednisolone or mycophenolate and he was admitted for investigation. MR cholangiopancreatography demonstrated areas of intrahepatic biliary tree beading and stricturing, in keeping with sclerosing cholangitis. Prednisolone and mycophenolate were stopped and ursodeoxycholic acid commenced with subsequent partial improvement of the patient\u2019s liver function tests.<\/jats:p>","DOI":"10.1136\/bcr-2021-241700","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T13:59:47Z","timestamp":1622210387000},"page":"e241700","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Sclerosing cholangitis in a patient treated with nivolumab"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-732X","authenticated-orcid":false,"given":"Sam","family":"Talbot","sequence":"first","affiliation":[{"name":"Gastroenterology, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivienne","family":"MacLaren","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Lafferty","sequence":"additional","affiliation":[{"name":"Gastroenterology, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"2025082803275169000_14.5.e241700.1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205143"},{"key":"2025082803275169000_14.5.e241700.2","unstructured":"SMC . Scottish medicines Consortium. SMC No. (1144\/16), 2016: 1\u201312."},{"key":"2025082803275169000_14.5.e241700.3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2025082803275169000_14.5.e241700.4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/gastro\/goz044","article-title":"Histologic patterns of liver injury induced by anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Gastroenterol Rep"},{"key":"2025082803275169000_14.5.e241700.5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cld.902","article-title":"Primary sclerosing cholangitis: epidemiology, genetics, diagnosis, and current management","volume":"15","author":"Gochanour","year":"2020","journal-title":"Clin Liver Dis"},{"key":"2025082803275169000_14.5.e241700.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.038"},{"key":"2025082803275169000_14.5.e241700.7","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"2025082803275169000_14.5.e241700.8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3348\/kjr.2016.17.1.25","article-title":"Sclerosing cholangitis: clinicopathologic features, imaging spectrum, and systemic approach to differential diagnosis","volume":"17","author":"Seo","year":"2016","journal-title":"Korean J Radiol"},{"key":"2025082803275169000_14.5.e241700.9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1148\/radiographics.20.4.g00jl04959","article-title":"Radiologic manifestations of sclerosing cholangitis with emphasis on Mr cholangiopancreatography","volume":"20","author":"Vitellas","year":"2000","journal-title":"Radiographics"},{"key":"2025082803275169000_14.5.e241700.10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317993"},{"key":"2025082803275169000_14.5.e241700.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21405"},{"key":"2025082803275169000_14.5.e241700.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-017-0583-8","article-title":"Secondary sclerosing cholangitis: a review of recent literature","volume":"19","author":"Brooling","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"2025082803275169000_14.5.e241700.13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082803275169000_14.5.e241700.14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"key":"2025082803275169000_14.5.e241700.15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-Related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"2025082803275169000_14.5.e241700.16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"2025082803275169000_14.5.e241700.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rcr2.560","article-title":"Pembrolizumab\u2010induced secondary sclerosing cholangitis in a non\u2010small cell lung cancer patient","volume":"8","author":"Matsumoto","year":"2020","journal-title":"Respirol Case Rep"},{"key":"2025082803275169000_14.5.e241700.18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","article-title":"Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis","volume":"58","author":"Kono","year":"2019","journal-title":"Intern Med"},{"key":"2025082803275169000_14.5.e241700.19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","article-title":"A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event","volume":"36","author":"Gelsomino","year":"2018","journal-title":"Invest New Drugs"},{"key":"2025082803275169000_14.5.e241700.20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025082803275169000_14.5.e241700.21","first-page":"439","article-title":"Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature","volume":"11","author":"Izumi","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025082803275169000_14.5.e241700.22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 Immunotherapy-Related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"},{"key":"2025082803275169000_14.5.e241700.23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2025082803275169000_14.5.e241700.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948"},{"key":"2025082803275169000_14.5.e241700.25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"2025082803275169000_14.5.e241700.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"2025082803275169000_14.5.e241700.27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-241700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:27:59Z","timestamp":1756376879000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-241700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,28]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bcr-2021-241700"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-241700","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}